2017 Volume 11 Issue 1 Pages 25-31
Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a severe cutaneous adverse drug reaction. SJS/TEN may cause fatal conditions with poor prognosis. Previous therapeutic guidelines for SJS/TEN have contributed to the improvement of prognosis. In 2016, the previous therapeutic guidelines for this disease were revised. The points of these revised guidelines were mentioned here. The first line of treatment for SJS/TEN is systemic corticosteroid administration, such as a high dose of steroid therapy and steroid pulse therapy, as it always has been. In the revised guidelines, a high dose of intravenous immunoglobulin (IVIg) has been introduced as an approved treatment modality. Regarding the usage, the IVIg administration is recommended to be added to the medium dose of steroid treatment. The timing of IVIg administration is indicated in the therapeutic algorithm. In addition, topical interventions for mucocutaneous lesions and ocular lesions detected in patients with SJS/TEN are also provided in the revised guidelines. The appropriate treatments for SJS/TEN may result in more favorable outcomes by utilizing the therapeutic guidelines.
